RETRACTED: Aseptic Meningitis Following Rozanolixizumab in a Patient With Refractory Anti-MuSK Positive Myasthenia Gravis: A Case Report

Abstract

Keywords

rozanolixizumab aseptic meningitis myasthenia gravis MuSK antibodies FcRn inhibitor case report

Get full access to this article

View all access options for this article.

References

Gilhus

Tzartos

Evoli

Palace

Burns

Verschuuren

JJGM

. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.

Howard

JFJ

Nowak

Wolfe

, et al. Rozanolixizumab for generalized myasthenia gravis. Lancet Neurol. 2023;22(2):135-147.

SAFETY . Rystiggo. 2024. https://www.rystiggohcp.com/safety. Accessed 24 August 2025 Published.

Kepa

Olesińska

, et al. Drug-induced aseptic meningitis: a review. Clin Rheumatol. 2020;39(11):3457-3464.

Noseda

Ripamonti

, et al. Aseptic meningitis following rituximab therapy: a case report and review. J Neurol Sci. 2011;308(1–2):161-163.

Sekul

Cupler

Dalakas

. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy. Ann Intern Med. 1994;121(4):259-262.

Anderson

Gold

Olson

Pisano

. Chronic aseptic meningitis caused by enterovirus in a humorally immunosuppressed adult patient. BMC Infect Dis. 2022;22(1):16. doi:10.1186/s12879-021-06956-1

Bril

Howard

Mantegazza

, et al. Safety profile of efgartigimod across clinical trials in generalized myasthenia gravis and other indications. Expert Opin Drug Saf. 2025;24(2):123-135. doi:10.1080/1744666X.2025.2497840

Huntemann

Gerischer

Herdick

, et al. C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2025;96(4):310-321. doi:10.1136/jnnp-2024-334404. Published 2025 Mar 24.

10.

Shah

Zhang

Davaro

. A case of drug-induced aseptic meningitis caused by rozanolixizumab in a patient with myasthenia gravis. AIM Clinical Cases. 2025;4(4):e240238. doi:10.7326/aimcc.2024.0238